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Lithium Therapy in Alzheimer's Disease
Ross Robison, fourth-year pharmacy student from Fort Wayne, Ind.; Sara Swick, fourth-year pharmacy student from
Pataskala, Ohio; Lauren Bajbus, fifth-year pharmacy student from Parma, Ohio; Jennifer Bauer, fifth-year pharmacy student
from St. Marys, Pa.; B. Shane Martin, PharmD, assistant professor of pharmacy practice
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder
with no known cure which has a strong impact on patients
and their caregivers. Current treatments for AD can slow the
disease progression, but cannot reverse the damage that has
already been done, resulting in some level of lifelong disability for affected patients. The use of lithium has shown promising results in mice models of AD. While animal models have
produced positive results, additional human trials need to be
conducted in order to determine a place for lithium in Alzheimer's disease therapy. Pharmacists should be aware of
this potential new use of lithium since this is a drug that requires intensive monitoring and has multiple drug interactions. By having knowledge of the rationale for using lithium
in Alzheimer's disease, pharmacists can be better equipped
to counsel patients and their caregivers.

Background
Alzheimer's disease (AD) is a progressive neurodegenerative
disorder which affects 2.4 to 5.1 million people in the United
States, according to the National Institute on Aging.1 AD is not
a normal part of aging; rather it is a disease causing dementia
characterized by a loss of cognition. This loss of cognition
may be serious enough to affect a patient's activities of daily
living (ADLs). AD affects the most recent memories first before progressing to other areas of the brain. Not only is AD
the leading cause of dementia in the elderly in America, but it
has also been tied to the deterioration of general cognitive
skills,1.2 Unfortunately, treatment of AD is limited to drugs
which function only to slow the progression of the disease
and abate symptoms, as there is no cure for the disease at the
present time.1 AD has been sub-classified into seven stages
by the Alzheimer's Association based on the most common
symptoms of the disease as it progresses. AD progression
may vary greatly, and patients may not experience the same
symptoms at any given stage of the disease. However, these
disease stage classifications may be helpful in determining
the course of action a practitioner may choose to take if a
patient presents with some of the symptoms along the continuum of progressive cognitive impairment.

Stage 1:

No impairment (normal function)
Patient experiences no memory problems and
does not show signs or symptoms of dementia.

Stage 2:

Very mild cognitive decline (age-related or the
earliest signs of Alzheimer's disease)
Memory lapses, such as forgetting familiar words,
are common but clinical examination does not
show signs of dementia.
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Stage 3:

Mild cognitive decline (early-stage Alzheimer's
may be diagnosed in some individuals with
these symptoms)
Clinical examination may detect problems in concentration or memory; friends, family or coworkers may begin to notice difficulties such as
problems remembering what was just read, increasing trouble organizing or difficulty performing tasks in social or work settings.

Stage 4:

Moderate cognitive decline (mild or earlystage Alzheimer's disease)
Medical review should be able to detect clear
problems in several areas such as forgetfulness of
recent events, impaired ability to perform challenging mental arithmetic, forgetfulness of one's
own history or becoming moody in socially or
mentally challenging situations.

Stage 5:

Moderately severe cognitive decline (moderate
or mid-stage Alzheimer's disease)
Patients may need help performing ADLs and gaps
in memory and thinking are noticeable. Individuals may be unable to recall their address or telephone number, become confused about where
they are or what day it is, or have trouble with less
challenging math, but may still remember significant details about themselves and their family.

Stage 6:

Severe cognitive decline (moderately severe or
mid-stage Alzheimer's disease)
Memory and thinking ability will continue to
worsen and patients may need help with ADLs,
which include use of the bathroom or dressing
properly. Patients may lose awareness of their
own surroundings, be able to distinguish faces of
family members but not be able to remember
names, experience behavioral or personality
changes, or experience major changes in sleep patterns.

Stage 7:

Very severe cognitive decline (severe or late
stage Alzheimer's disease)
Individuals lose the ability to respond to their environment, carry on a conversation and eventually
control movement. Patients need help with most
of their daily activities and no longer recognize
their closest relatives and friends.

Etiology of Alzheimer's Disease
AD is characterized clinically by three main hallmarks which
lead to decreased cholinergic neurotransmission: buildup of
amyloid-~-peptides (A~), neurofibrillary tangles from a hy-
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perphosphorylated tau protein and degeneration of cholinergic neurons.1.3-5 Extracellular buildup of AP originates from
the cleavage of the amyloid precursor protein (APP).2,3 A~
then accumulates in the brain and forms neuritic plaques
which slow the brain's cognitive function by inhibiting neurologic pathways.3.4 Alteration in synaptic function may also
be due to the intracellular neurofibrillary tangles from a hyperphosphorylated tau protein, a microtubule associated
protein, which misfolds and disassembles from microtubules
when hyperphosphorylated. This misfolding and disassociation of the tau protein in the brain forms aggregates and
therefore alters overall synaptic transmission and function.3,6,7 Additionally, levels of brain-derived neurotrophic
factor (BDNF) and mRNA are diminished in both the brain
and serum of Alzheimer's patients.6 BDNF is a neurogenerative agent which plays an important role in neuronal growth,
survival and differentiation. Low levels in the body may result in neurodegeneration and a decrease in neurotrophic
function. Buildup of AP neuritic plaques from the cleavage of
APP, neurofibrillary tangles from an aggregation of disassociated tau protein and a decrease of serum BDNF have been
shown to decrease the rate and efficiency of cholinergic neurotransmission.3·4·6
The increased expression of glycogen synthase kinase-3p
(GSK-3P) is an important consideration in AD because GSK3~ has been shown to be a predominant tau-kinase in the
brain and has more recently been shown to be involved with
the formation of Ap.5.8 GSK-3P is a serine-threonine kinase
responsible for phosphorylating both tau and APP, and is a
necessary component of a variety of intracellular signaling
pathways.4 Over-expression of GSK-3~ may cause hyperphosphorylation of tau and APP which results in aggregation
of extracellular neuritic plaques ;is well as intracellular neurofibrillary tangles, which are both clinical markers of AD.3,4
Due to this relationship of increased expression of GSK-3~
and the major clinical markers of AD, a variety of studies
have looked at the effects of dysfunctional GSK-3P on the
progression and treatment of the disease by testing the inhibition of GSK-3p. Studies have shown that over-expression of
GSK-3~ is associated with neurodegeneration and aggregation of neurofibrillary tangles similar to AD and other dementias, making this protein a primary drug target for AD.3-5,8

Lithium
Lithium has been used in the treatment of mood disorders
since 1949 and has remained first-line therapy of bipolar
disorders up to present day.5.6 It has known neuroprotective
effects, but the overall mechanism is still largely unknown. It
has been shown to inhibit GSK-3P both directly and indirectly which is the reason for introducing lithium into the
Alzheimer's population as a possible treatment. 4,S,8 Direct
inhibition of GSK-3~ occurs when lithium competes with the
magnesium ion for one of two magnesium binding sites on
the kinase.5 While a variety of drugs appear to have this
direct inhibitory mechanism, the indirect inhibition of GSK3 p remains exclusive to lithium. The proposed mechanism of
indirect inhibition is that lithium increases the N-terminal
serine phosphorylation of GSK-3p, thereby allosterically
inactivating the enzyme. The specific mechanism by which
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lithium exerts this
investigation.
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This combination of direct and indirect inhibition of the GSK3p enzyme has been shown to protect against AP injury or
neurotoxicity and has also been shown to reduce the amount
of phosphorylated tau in vitro and in vivo.z.s Lithium is a complex molecule with many cellular effects, a high potential for
toxicity and a narrow therapeutic range. Even levels within
the narrow therapeutic range of 0.5 to 1.5 mmol/L may result in adverse effects such as diabetes insipidus, thyroid toxicity and imbalances in calcium and other electrolytes.8
Therefore, there is a need to monitor serum levels via blood
draws every four to five days during initial therapy. There
are also strict dosage adjustments for patients with renal
impairment because of the high potential for adverse effects.9

Alzheimer's and Lithium
It has been observed that there is a reduced prevalence of AD
in bipolar patients on lithium therapy.6 This observed correlation has recently led researchers to study the possibility of
using lithium to treat Alzheimer's Disease. Mouse and cultured nerve studies have been useful in gathering significant
data. However, human trials have been a little more difficult
to assess and cause a number of questions to be raised upon
analyzing the results.
Mice trials have helped to illustrate the effects of GSK-3~ on
AD. In mice, over-expression of GSK-3P induces neurodegeneration. Results showed a reduction of A~ in the hippocampus and cortex, less neuritic aggregates, less plaque buildup
and decreased glial inflammatory reactions in mice treated
with lithium to inhibit GSK-3~ expression compared to control mice.3 The mice treated with lithium not only showed
significant reduction in AD markers, but also showed improvement of spatial memory. This data suggests lithium
may have an important role in slowing progression of AD.
Lithium has also been seen to induce BDNF production in
cultured neurons and rodent models.6 As previously stated,
BDNF protects neurons from injury. In postmortem analyses
of AD patients, BDNF levels were diminished in brain and
serum samples. A randomized, patient-only blinded human
trial was performed treating AD patients for 10 weeks with
lithium. The results showed a significant increase in BDNF
serum levels compared to baseline.
The in vitro evidence shows lithium significantly reduces AD
characteristics and markers.3,6,8Despite the fact that studies
were conducted for an appropriate length, the disease state
itself has resulted in a high dropout rate making the data collected difficult to use in assessing significance. One randomized trial of 27 patients lasted 12 weeks and measured BDNF
serum levels and cognitive impairment using the Alzheimer's
Disease Assessment Scale-cognitive subscale (ADAS-Cog)
method. 6 Patients were started on lithium sulfate 42 mg
twice daily and researchers used a six-week titration phase
to reach targeted serum levels of 0.5 to 0.8 mmolf L. There
were two dropouts in this study; one was discontinued at
week eight for unknown reason beyond unwillingness to
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continue, one other dropout was reported due to a serious
adverse event of severe aggression and hallucinations at
week seven. The results reported a statistically significant
increase in BDNF serum levels and a decrease in cognitive
impairment with lithium treatment compared to the placebo
group. An open-label trial was conducted of 22 patients lasting longer than 12 months looking at the feasibility of using
lithium in treating AD.B Patients were instructed to continue
their daily medication regimen, but these specific medications were not documented. A specific dosing regimen for
lithium was not established during the trial. Patients were
started on low dose lithium carbonate 100 mg and serum
levels were assessed every two weeks to reach target levels
of 0.3 to 0.8 mmoljL. They started the screening process
with 480 patients and excluded 458 patients for failing to
meet entry screening lab levels, not wanting to participate
due to frequency of assessment, compliance issues and patients with a concomitant illness or therapy that was contraindicated with lithium treatment. There were a total of 14
dropouts in this study, including two deaths unrelated to
treatment. The other 12 dropouts were due to hospital admissions unrelated to treatment or relatives or investigators
removing them from treatment. The authors of this trial concluded lithium was safe when dosages were kept within the
therapeutic range and that side effects were mild and not the
main cause of withdrawal from the study. However, with the
high dropout rate and only eight patients completing the
trial, these conclusions are debatable. Although there is a
significant amount of literature available on this topic, more
randomized, controlled human trials should be performed in
AD patients even though the in vitro and in vivo studies suggest lithium may decrease the characteristics and disease
progression of AD.
Pharmacy Implications and Counseling
Since AD is a disease state of the elderly, it is important to
monitor side effects, as they may be greater in the elderly
population due to comorbid disease states, interactions with
other drugs and a higher probability of dehydration. It is important to counsel patients on the importance of staying hydrated in order to avoid kidney stones and toxicity. Due to
the narrow therapeutic range of lithium, it is important to
review a patient's current medication profile and history of
present illness in order to assess potential precautions. Some
precautions with the use of lithium include thiazide diuretics,
thyroid disease, renal impairment and heart disease.s.9 It is
also important to make sure the dosing schedule results in
drug concentrations within the therapeutic range to avoid
neurotoxic effects. Pharmacists and physicians also should
ensure labs are being drawn as recommended in order to
adjust the dose as necessary. Lithium serum level monitoring, while imperative, is a major deterrent from use since it
requires frequent blood draws which may be undesirable to
the patient.9

while a non-thiazide or potassium sparing diuretic can be
used for the adverse effects of diabetes insipidus.1,9 Lithium
has also been proven to help treat agitation and aggression
associated with dementia.7 Overall, the literature suggests
lithium may be a helpful adjunct for slowing the progression
of AD. When used with the appropriate therapeutic range, it
may prevent progression and possibly reverse AD characteristics.
Conclusion
There is still no cure for AD; it is a progressive neurodegenerative disorder affecting the most recent memories first and
working its way to other areas of the brain. The use of lithium in slowing the progression of AD has been successful in
mice studies and more research is being done to see if similar
results will be seen in human trials. Researchers believe lithium to display the neuroprotective effects of inhibiting GSK3~ and inducing BDNF production; therefore, it may have the
potential for use early in AD treatment. While lithium may be
able to help patients with the management of AD, it is important that pharmacists check for contraindications, counsel
patients on staying hydrated and help patients manage their
AD symptoms to have a better overall quality oflife.
References
1. General Information on Alzheimer's disease. National Institute on
Aging. 2010. Available atwww.nianih.gov/Alzheimers/Alzheimerslnformation
/Generallnfo. Accessed 25 Oct 2011.
2. Toledo EM, Inestrosa NC. Activation of Wntsignaling by lithium and
rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of APPswe/PSENlt.E9 mouse model of Alzheimer's disease. Mo/ Psychiatr. 2010;15:272-85.
3. EngelT, Gofii-Oliver P, de BarredaEG, Lucas JI, Hernandez F, Avila ).
Lithium, a potential protective drug in Alzheimer's disease. Neurodegener Dis. 2008;5:247-9.
4.
Mendes CT, Mury FB, de Sa Moreira E, Alberto FL, Forlenza OV, DiasNeto E, Gattaz WF. Lithium reduces Gsk3b mRNA levels: implications
for Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2009;259:16
-22.
5.
Martinez A, Perez DI. GSK-3 inhibitors: a ray of hope for the treatment
of Alzheimer's disease?] Alzheimers Dis. 2008;15:181-91.
6. Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H, Laske
C. Increase of BDNF serum concentration in lithium treated patients
with early Alzheimer's disease.] Alzheimers Dis. 2009;16:649-56.
7.
Maruyama M, lshizawa K, Tomita N, Nemoto M, Yasuda H, Ebihara S, et
al. Lithium therapy and cerebrospinal fluid biomarker levels in Alzheimer's disease. Geriatr Gerentol lnt. 2005;5:298-300.
8.
Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S.
A feasibility and tolerability study of lithium and Alzheimer's disease.
Int] Geriatr Psychiatry. 2008;23:704-11.
9.
Lithium [monograph]. Hudson (OH): Lexi-Comp; 2011 [cited 2011 Oct
25]. Available at: crlonline.com/crlsqljservlet/crlonline.

Lithium treatment is focused on slowing disease progression,
but patients may continue to exhibit symptoms associated
with AD. Health care professionals can help treat some of the
symptoms of AD to make the patient more comfortable. For
example, hand tremors can be treated with propranolol,
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